These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 32437476)

  • 1. From trivalent to quadrivalent influenza vaccines: Public health and economic burden for different immunization strategies in Spain.
    Crépey P; Redondo E; Díez-Domingo J; Ortiz de Lejarazu R; Martinón-Torres F; Gil de Miguel Á; López-Belmonte JL; Alvarez FP; Bricout H; Solozabal M
    PLoS One; 2020; 15(5):e0233526. PubMed ID: 32437476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness of Quadrivalent versus Trivalent Influenza Vaccine in the United States.
    de Boer PT; Crépey P; Pitman RJ; Macabeo B; Chit A; Postma MJ
    Value Health; 2016 Dec; 19(8):964-975. PubMed ID: 27987647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of quadrivalent influenza vaccine in Spain.
    García A; Ortiz de Lejarazu R; Reina J; Callejo D; Cuervo J; Morano Larragueta R
    Hum Vaccin Immunother; 2016 Sep; 12(9):2269-77. PubMed ID: 27184622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness evaluation of quadrivalent influenza vaccines for seasonal influenza prevention: a dynamic modeling study of Canada and the United Kingdom.
    Thommes EW; Ismaila A; Chit A; Meier G; Bauch CT
    BMC Infect Dis; 2015 Oct; 15():465. PubMed ID: 26503131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of quadrivalent influenza vaccines in Brazil: a cost-effectiveness analysis using an influenza transmission model.
    Crépey P; Boiron L; Araujo RR; Lopez JG; Petitjean A; de Albuquerque Luna EJ
    BMC Public Health; 2020 Sep; 20(1):1374. PubMed ID: 32907562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of quadrivalent versus trivalent influenza vaccine in Taiwan: A lifetime multi-cohort model.
    Yang MC; Tan EC; Su JJ
    Hum Vaccin Immunother; 2017 Jan; 13(1):81-89. PubMed ID: 27624648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Public health and economic impact of seasonal influenza vaccination with quadrivalent influenza vaccines compared to trivalent influenza vaccines in Europe.
    Uhart M; Bricout H; Clay E; Largeron N
    Hum Vaccin Immunother; 2016 Sep; 12(9):2259-68. PubMed ID: 27166916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of switching from trivalent to quadrivalent inactivated influenza vaccines for the at-risk population in Italy.
    Mennini FS; Bini C; Marcellusi A; Rinaldi A; Franco E
    Hum Vaccin Immunother; 2018; 14(8):1867-1873. PubMed ID: 29708843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of quadrivalent influenza vaccine on public health and influenza-related costs in Australia.
    Jamotte A; Chong CF; Manton A; Macabeo B; Toumi M
    BMC Public Health; 2016 Jul; 16():630. PubMed ID: 27449665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of quadrivalent influenza vaccine in Hong Kong - A decision analysis.
    You JH; Ming WK; Chan PK
    Hum Vaccin Immunother; 2015; 11(3):564-71. PubMed ID: 25714506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Effectiveness of Quadrivalent Versus Trivalent Influenza Vaccination in the Dutch National Influenza Prevention Program.
    Zeevat F; Crépey P; Dolk FCK; Postma AJ; Breeveld-Dwarkasing VNA; Postma MJ
    Value Health; 2021 Jan; 24(1):3-10. PubMed ID: 33431150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost Effectiveness of Quadrivalent Influenza Vaccines Compared with Trivalent Influenza Vaccines in Young Children and Older Adults in Korea.
    Kim YK; Song JY; Jang H; Kim TH; Koo H; Varghese L; Han E
    Pharmacoeconomics; 2018 Dec; 36(12):1475-1490. PubMed ID: 30251078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of quadrivalent influenza vaccination in at-risk adults and the elderly: an updated analysis in the U.K.
    Meier G; Gregg M; Poulsen Nautrup B
    J Med Econ; 2015; 18(9):746-61. PubMed ID: 25903831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-Utility of Quadrivalent Versus Trivalent Influenza Vaccine in Germany, Using an Individual-Based Dynamic Transmission Model.
    Dolk C; Eichner M; Welte R; Anastassopoulou A; Van Bellinghen LA; Poulsen Nautrup B; Van Vlaenderen I; Schmidt-Ott R; Schwehm M; Postma M
    Pharmacoeconomics; 2016 Dec; 34(12):1299-1308. PubMed ID: 27647004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of quadrivalent versus trivalent influenza vaccine for elderly population in China.
    Jiang M; Li P; Wang W; Zhao M; Atif N; Zhu S; Fang Y
    Vaccine; 2020 Jan; 38(5):1057-1064. PubMed ID: 31787414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switching from trivalent to quadrivalent inactivated influenza vaccines in Uruguay: a cost-effectiveness analysis.
    Bianculli PM; Bellier L; Mangado IO; Pérez CG; Mieres G; Lazarov L; Petitjean A; Dibarboure H; Lopez JG
    Hum Vaccin Immunother; 2022 Nov; 18(5):2050653. PubMed ID: 35344679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis of quadrivalent influenza vaccine versus trivalent influenza vaccine for elderly in Hong Kong.
    You JH; Ming WK; Chan PK
    BMC Infect Dis; 2014 Nov; 14():618. PubMed ID: 25420713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost Utility of Switching From Trivalent to Quadrivalent Influenza Vaccine in Turkey.
    Amiche A; Tanriover MD; Bellier L; Ugur B; Akin L
    Value Health Reg Issues; 2021 Sep; 25():15-22. PubMed ID: 33485248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cost-effectiveness analysis of quadrivalent influenza vaccination for older adults aged 60 and above in mainland China].
    Yan H; Yang J; Chen ZY; Gong H; Zhong GJ; Yu HJ
    Zhonghua Yi Xue Za Zhi; 2021 Aug; 101(30):2405-2412. PubMed ID: 34404135
    [No Abstract]   [Full Text] [Related]  

  • 20. Public health and budget impacts of switching from a trivalent to a quadrivalent inactivated influenza vaccine in Paraguay.
    Arbo A; Martinez-Cuellar C; Vazquez C; Bellier L; Adorno C; Dibarboure H; Lopez JG; Petitjean A; Bianculli P
    Hum Vaccin Immunother; 2022 Nov; 18(5):2069974. PubMed ID: 35543602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.